PeptidePedia The community reference

Contributions of eGFR_Esme

User contributions·27 logged edits·page 1 of 1

Contributions by eGFR_Esme, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 6,540 edits includes activity predating the current log.

  1. 21:54, 22 Jul 2026 (diff | hist) Shenzhen Hybio Pharmaceutical 17,718 +2 m add the reception tally with its period and count stated
  2. 05:21, 18 Jul 2026 (diff | hist) Preparative HPLC purification 4,882 ±0 m state that overlay gas is used and name it
  3. 17:17, 13 Jul 2026 (diff | hist) Insulin syringe 4,944 ±0 clarify that the figure is per dose, not per vial
  4. 04:51, 13 Jul 2026 (diff | hist) LEADER trial 4,799 ±0 de-duplicate a repeated sentence
  5. 16:12, 21 Jun 2026 (diff | hist) Solid-phase peptide synthesis 5,359 ±0 unpipe a link that did not need piping
  6. 10:30, 28 May 2026 (diff | hist) Talk:FLOW trial 537 +150 /* The initial eGFR dip */ new section
  7. 08:36, 21 May 2026 (diff | hist) Talk:Cold chain 1,507 +232 /* Domestic refrigerator claim: which studies? */ reply
  8. 10:15, 13 May 2026 (diff | hist) Talk:Contraindications of incretin therapy 537 +138 /* Renal caution is indirect */ new section
  9. 09:21, 30 Mar 2026 (diff | hist) Injection site rotation 4,872 ±0 rm the individualised advice — the article describes, it does not instruct
  10. 13:10, 18 Mar 2026 (diff | hist) Talk:C-peptide 611 +91 /* Renal clearance caveat */ reply
  11. 07:02, 15 Mar 2026 (diff | hist) C-peptide 4,400 ±0 attribute the population interval to the cohort it was derived from
  12. 22:44, 8 Mar 2026 (diff | hist) Number needed to treat 4,718 ±0 add the trial registration identifier
  13. 09:50, 25 Feb 2026 (diff | hist) Talk:LEADER trial 400 +157 /* Renal signal was a marker */ new section
  14. 06:31, 23 Feb 2026 (diff | hist) International nonproprietary name 4,356 ±0 m add the molecular formula to the infobox
  15. 00:22, 14 Oct 2025 (diff | hist) Body composition assessment 5,029 ±0 expand §Lean mass loss during weight reduction
  16. 08:54, 17 Sep 2025 (diff | hist) PolyPeptide Group (Hangzhou) 3,664 +976 state what the certificate supplied with orders carries
  17. 11:27, 27 Aug 2025 (diff | hist) Test report forgery 5,391 +336 add the citation for the blind-sampling discussion
  18. 00:14, 5 Jul 2025 (diff | hist) Sarcopenia 3,762 ±0 add category for laboratory medicine
  19. 00:04, 2 Jul 2025 (diff | hist) Injection site rotation 4,626 +562 correct the needle gauge given for subcutaneous administration
  20. 04:45, 16 Jun 2025 (diff | hist) Sarcopenia 3,762 ±0 attribute the population interval to the cohort it was derived from
  21. 20:42, 5 May 2025 (diff | hist) USP General Chapter 71 3,363 ±0 give the injection volume, without which the loading cannot be judged
  22. 00:27, 25 Feb 2025 (diff | hist) Tianjin Finder Chemical 6,469 +301 add the research-use-only statement to the lead rather than only the footer
  23. 18:30, 1 Feb 2025 (diff | hist) Body composition assessment 3,353 ±0 add the standardisation programme the assay is traceable to
  24. 22:23, 25 Jan 2025 (diff | hist) Beyond-use date 9,787 +900 add the dead-space volume to the worked example
  25. 17:16, 27 Dec 2024 (diff | hist) Prior authorisation 1,792 +767 m add the note that prices below the list price are not evidence of a counterfeit
  26. 15:31, 20 Nov 2024 (diff | hist) Cold chain 15,523 +1,581 add the crimp-seal step to the fill-and-finish description
  27. 06:22, 21 Oct 2024 (diff | hist) WuXi TIDES 5,922 +1,329 rm the price; supplier articles carry no price per PP:VN